EMBARGOED FOR RELEASE UNTIL 3 PM ET, April 14, 2005
Hormone Aids Recovery in Rats with Hemorrhagic Stroke
Embargoed for Release until 3:15 P.M. ET, Thursday, April 14, 2005
Miami Beach – Erythropoietin, a glycoprotein hormone that stimulates bone marrow to produce red blood cells, has shown a therapeutic effect on rats who have suffered an intracerebral hemorrhage, according to research that will be presented at the American Academy of Neurology 57th Annual Meeting in Miami Beach, Fla., April 9 – 16, 2005. The study examined whether erythropoietin might have a neuroprotective effect and improve functional recovery in rats following an intracerebral hemorrhage, which is a type of stroke. “This is the first evidence that erythropoietin has a therapeutic effect in hemorrhagic stroke,” said study authors Dong-In Sinn, MD, and Jae-Kyu Roh, MD, of the Stroke & Neural Stem Cell Laboratory, Department of Neurology at Seoul National University Hospital. Erythropoietin was administered to adult rats after they had an intracerebral hemorrhage and then for 4 to 14 days in the test group. Results showed that the size of the hemorrhage was decreased in rats treated with erythropoietin by 25 percent at three days after the stroke, and improvements were seen in brain water content and decreases in damaged cells. The erythropoietin-treated rats also showed greater recovery in behavioral and functional tests. “Our result suggests that erythropoietin could be a novel drug for treatment of hemorrhagic stroke. It not only reduces inflammation and cell death, but also improves functional recovery after stroke,” said Sinn. The study was supported by the 21st Century Frontier Research Fund of the Ministry of Science and Technology, Republic of Korea.
The American Academy of Neurology is the world's largest association of neurologists and neuroscience professionals, with 32,000 members. The AAN is dedicated to promoting the highest quality patient-centered neurologic care. A neurologist is a doctor with specialized training in diagnosing, treating and managing disorders of the brain and nervous system such as Alzheimer's disease, stroke, migraine, multiple sclerosis, concussion, Parkinson's disease and epilepsy.
Editor's Notes:Dr. Sinn will present this research during a scientific platform session at 3:15 p.m. on Thursday, April 14 in Room D129 of the Miami Beach Convention Center. All listed times are Eastern Time (ET).